Physician profile
Douglas E Rennels
NPI 1023191608
$435.11
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $40.69.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $125.07 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $74.32 | 2019-2020 | |
| Zyla Life Sciences, INC. | $49.97 | 2019 | |
| Arbor Pharmaceuticals, INC. | $40.57 | 2019 | |
| Collegium Pharmaceutical, INC. | $39.60 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $35.46 | 2019 | |
| Shionogi INC | $16.32 | 2019 | |
| Scilex Pharmaceuticals INC. | $16.15 | 2019 | |
| Daiichi Sankyo INC. | $13.40 | 2019 | |
| Sentynl Therapeutics, INC. | $12.43 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.82 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Rennels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.